Stay updated on Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial
Sign up to get notified when there's something new on the Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial page.

Latest updates to the Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 is now shown. The previously displayed notices about government funding lapse (v3.4.1) have been removed.SummaryDifference0.3%

- Check21 days agoChange DetectedThe page now shows an administrative notice about a lapse in government funding and an updated revision tag (v3.4.1) replacing v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check28 days agoChange DetectedThe update adds a glossary display option and updates several page labels and revision text, for example 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0', while older labels like 'No FEAR Act Data' are removed.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; this minor version change does not affect page content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check64 days agoChange DetectedAdded a Locations section with a Texas site; removed the Texas Locations section and the HHS Vulnerability Disclosure link, and updated the revision to v3.3.3.SummaryDifference0.2%

- Check92 days agoChange DetectedAn editorial note was added that publications are automatically filled from PubMed, and the page revision was updated to v3.3.2. The previous wording about PubMed publications and automatic listing by ClinicalTrials.gov was removed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial page.